Healthcare is Irrational
One Medical acquired Iora Health, a surprising integration of two vastly different companies that does not make sense at first...
Medical Devices & Patient Advocacy
If perception is reality, then the changing perception of post-pandemic healthcare has ushered in a new reality for the medical...
Disparity Masquerading As Equity
There is much talk about healthcare equity, and the importance of access in healthcare. But access means different things to...
The Fault In Our Letters
The WHO has introduced nomenclature redefining COVID-19 variants to prevent prejudices formed during the pandemic. But a close examination reveals...
Vaccine Diplomacy
The great game is now upon us, with the United States entering the fray of international vaccine diplomacy, doling vaccines...
The Pandemic Can Solve Healthcare’s Problems
To find meaning in suffering is to transcend it. Something we can do in healthcare now that the pandemic seems...
Brave New World
America is the land of optimism, with an undeniable taste for dystopian futures. One which pits technological advancements in medicine...
Medium is the Message
Today Dr. Deborah Birx is known for many things. But earlier she was known as the country's leading voice for...
Healthcare is Woke
Healthcare is now fully engaged in many of the social justice issues grappling the country. A move generally seen to...
CDC About Face
The CDC issued a recent revision to the mask mandate, lifting many of the preexisting requirements. A move met with...
Databases for Healthcare Uncertainty
Data drives healthcare, whether it is individual decisions or broader health policies. But data only tells us what we know,...
Healthcare Data as Healthcare Inequity
We can now see how post-pandemic healthcare will look. Data platforms will grow in sophistication alongside a growing distrust in...
Videos
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more